101 related articles for article (PubMed ID: 1705175)
1. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
Ghetie MA; Uhr JW; Vitetta ES
Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
[TBL] [Abstract][Full Text] [Related]
2. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
7. Binding of IL-1 beta to alpha-macroglobulins and release by thioredoxin.
Borth W; Scheer B; Urbansky A; Luger TA; Sottrup-Jensen L
J Immunol; 1990 Dec; 145(11):3747-54. PubMed ID: 1700994
[TBL] [Abstract][Full Text] [Related]
8. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
9. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
10. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
13. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
15. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
Ghetie V; Engert A; Schnell R; Vitetta ES
Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
[TBL] [Abstract][Full Text] [Related]
16. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Soler-Rodríguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
19. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
Ghetie V; Swindell E; Uhr JW; Vitetta ES
J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
[TBL] [Abstract][Full Text] [Related]
20. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]